Zobrazeno 1 - 10 of 151 pro vyhledávání: '"Saikatendu K"'
1
Akademický článek
Discovery of a Druggable, Cryptic Pocket in SARS-CoV-2 nsp16 Using Allosteric Inhibitors.
Autor: Inniss NL; Department of Microbiology-Immunology and Center for Structural Biology of Infectious Diseases, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, United States., Kozic J; Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague 6, 160 00, Czech Republic., Li F; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada., Rosas-Lemus M; Department of Microbiology-Immunology and Center for Structural Biology of Infectious Diseases, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, United States., Minasov G; Department of Microbiology-Immunology and Center for Structural Biology of Infectious Diseases, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, United States., Rybáček J; Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague 6, 160 00, Czech Republic., Zhu Y; WuXi AppTec Co., Ltd, China (Shanghai) Pilot Free Trade Zone, Shanghai, 201308, China., Pohl R; Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague 6, 160 00, Czech Republic., Shuvalova L; Department of Pharmacology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, United States., Rulíšek L; Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague 6, 160 00, Czech Republic., Brunzelle JS; Northwestern Synchrotron Research Center, Life Sciences Collaborative Access Team, Northwestern University, Argonne, Illinois 60439, United States., Bednárová L; Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague 6, 160 00, Czech Republic., Štefek M; Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague 6, 160 00, Czech Republic., Kormaník JM; Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague 6, 160 00, Czech Republic., Andris E; Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague 6, 160 00, Czech Republic., Šebestík J; Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague 6, 160 00, Czech Republic., Li ASM; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.; Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada., Brown PJ; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada., Schmitz U; Structural Chemistry, Gilead Pharmaceuticals, San Mateo, California 94404, United States., Saikatendu K; Takeda Development Center Americas, Inc., San Diego, California 92121, United States., Chang E; Takeda Development Center Americas, Inc., San Diego, California 92121, United States., Nencka R; Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague 6, 160 00, Czech Republic., Vedadi M; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.; Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada., Satchell KJF; Department of Microbiology-Immunology and Center for Structural Biology of Infectious Diseases, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, United States.
Publikováno v: ACS infectious diseases [ACS Infect Dis] 2023 Oct 13; Vol. 9 (10), pp. 1918-1931. Date of Electronic Publication: 2023 Sep 20.
Zobrazit plný text záznamu
2
Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit.
Autor: Hall MD; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA., Anderson JM; Office of the Director, National Institutes of Health, Bethesda, Maryland, USA., Anderson A; Pfizer Vaccine Research and Development, Pfizer, Pearl River, New York, USA., Baker D; University of Washington, Seattle, Washington, USA., Bradner J; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA., Brimacombe KR; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA., Campbell EA; The Rockefeller University, New York, New York, USA., Corbett KS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Carter K; Evotec, Lyon, France., Cherry S; University of Pennsylvania, Philadelphia, Pennsylvania, USA., Chiang L; Evrys Bio, Doylestown, Pennsylvania, USA., Cihlar T; Gilead Sciences, Foster City, California, USA., de Wit E; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA., Denison M; Vanderbilt University, Nashville, Tennessee, USA., Disney M; Scripps Research, Jupiter, Florida, USA., Fletcher CV; University of Nebraska Medical Center, Omaha, Nebraska, USA., Ford-Scheimer SL; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA., Götte M; University of Alberta, Edmonton, Alberta, Canada., Grossman AC; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA., Hayden FG; University of Virginia, Charlottesville, Virginia, USA., Hazuda DJ; Merck & Co, Inc, Kenilworth, New Jersey, USA., Lanteri CA; Walter Reed Army Institute of Research, Silver Spring, Maryland, USA., Marston H; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Mesecar AD; Purdue University, West Lafayette, Indiana, USA., Moore S; University of Alabama at Birmingham, Birmingham, Alabama, USA., Nwankwo JO; 1910 Genetics, Inc, Cambridge, Massachusetts, USA., O'Rear J; US Food and Drug Administration, Silver Spring, Maryland, USA., Painter G; Emory University, Atlanta, Georgia, USA., Singh Saikatendu K; Takeda California, Inc, San Diego, California, USA., Schiffer CA; University of Massachusetts Medical School, Worcester, Massachusetts, USA., Sheahan TP; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA., Shi PY; University of Texas Medical Branch, Galveston, Texas, USA., Smyth HD; University of Texas at Austin, Austin, Texas, USA., Sofia MJ; Arbutus Biopharma, Inc, Warminster, Pennsylvania, USA., Weetall M; PTC Therapeutics, Inc, South Plainfield, New Jersey, USA., Weller SK; University of Connecticut School of Medicine, Farmington, Connecticut, USA., Whitley R; University of Alabama at Birmingham, Birmingham, Alabama, USA., Fauci AS; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Austin CP; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA., Collins FS; Office of the Director, National Institutes of Health, Bethesda, Maryland, USA., Conley AJ; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Davis MI; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Publikováno v: The Journal of infectious diseases [J Infect Dis] 2021 Jul 15; Vol. 224 (Supplement_1), pp. S1-S21.
Zobrazit plný text záznamu
3
Akademický článek
Structure-Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]Pyridin-2-one-Based p38 MAP Kinase Inhibitors: Part 2.
Autor: Kaieda A; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Takahashi M; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Fukuda H; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Okamoto R; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Morimoto S; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Gotoh M; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Miyazaki T; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Hori Y; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Unno S; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Kawamoto T; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Tanaka T; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Itono S; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Takagi T; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Sugimoto H; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Okada K; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Lane W; Takeda California, 10410 Science Center Drive, San Diego, CA 92121, USA., Sang BC; Takeda California, 10410 Science Center Drive, San Diego, CA 92121, USA., Saikatendu K; Takeda California, 10410 Science Center Drive, San Diego, CA 92121, USA., Matsunaga S; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Miwatashi S; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan.
Publikováno v: ChemMedChem [ChemMedChem] 2019 Dec 17; Vol. 14 (24), pp. 2093-2101. Date of Electronic Publication: 2019 Nov 07.
Zobrazit plný text záznamu
4
Akademický článek
Discovery of Potent, Selective, and Brain-Penetrant 1 H-Pyrazol-5-yl-1 H-pyrrolo[2,3- b]pyridines as Anaplastic Lymphoma Kinase (ALK) Inhibitors.
Autor: Fushimi M; Neuroscience Drug Discovery Unit, Research , Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa , Kanagawa 251-8555 , Japan., Fujimori I; Neuroscience Drug Discovery Unit, Research , Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa , Kanagawa 251-8555 , Japan., Wakabayashi T; Neuroscience Drug Discovery Unit, Research , Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa , Kanagawa 251-8555 , Japan., Hasui T; Neuroscience Drug Discovery Unit, Research , Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa , Kanagawa 251-8555 , Japan., Kawakita Y; Neuroscience Drug Discovery Unit, Research , Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa , Kanagawa 251-8555 , Japan., Imamura K; Neuroscience Drug Discovery Unit, Research , Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa , Kanagawa 251-8555 , Japan., Kato T; Neuroscience Drug Discovery Unit, Research , Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa , Kanagawa 251-8555 , Japan., Murakami M; Neuroscience Drug Discovery Unit, Research , Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa , Kanagawa 251-8555 , Japan., Ishii T; Neuroscience Drug Discovery Unit, Research , Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa , Kanagawa 251-8555 , Japan., Kikko Y; Neuroscience Drug Discovery Unit, Research , Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa , Kanagawa 251-8555 , Japan., Kasahara M; Neuroscience Drug Discovery Unit, Research , Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa , Kanagawa 251-8555 , Japan., Nakatani A; Neuroscience Drug Discovery Unit, Research , Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa , Kanagawa 251-8555 , Japan., Hiura Y; Neuroscience Drug Discovery Unit, Research , Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa , Kanagawa 251-8555 , Japan., Miyamoto M; Neuroscience Drug Discovery Unit, Research , Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa , Kanagawa 251-8555 , Japan., Saikatendu K; Takeda California, Inc. , 10410 Science Center Drive , San Diego , California 92121 , United States., Zou H; Takeda California, Inc. , 10410 Science Center Drive , San Diego , California 92121 , United States., Lane SW; Takeda California, Inc. , 10410 Science Center Drive , San Diego , California 92121 , United States., Lawson JD; Takeda California, Inc. , 10410 Science Center Drive , San Diego , California 92121 , United States., Imoto H; Neuroscience Drug Discovery Unit, Research , Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa , Kanagawa 251-8555 , Japan.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2019 May 23; Vol. 62 (10), pp. 4915-4935. Date of Electronic Publication: 2019 May 03.
Zobrazit plný text záznamu
5
Akademický článek
Donated chemical probes for open science.
Autor: Müller S; Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt, Frankfurt am Main, Germany., Ackloo S; Structural Genomics Consortium, University of Toronto, Toronto, Canada., Arrowsmith CH; Department of Medical Biophysics, University of Toronto, Toronto, Canada., Bauser M; Drug Discovery Pharmaceuticals, Bayer AG, Berlin, Germany., Baryza JL; Vertex Pharmaceuticals, Boston, United States., Blagg J; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom., Böttcher J; Discovery Research, Boehringer Ingelheim, Vienna, Austria., Bountra C; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom., Brown PJ; Structural Genomics Consortium, University of Toronto, Toronto, Canada., Bunnage ME; Vertex Pharmaceuticals, Boston, United States., Carter AJ; Discovery Research, Boehringer Ingelheim, Ingelheim am Rhein, Germany., Damerell D; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom., Dötsch V; Institute of Biophysical Chemistry, Goethe-University, Frankfurt am Main, Germany.; Center for Biomolecular Magnetic Resonance, Goethe University, Frankfurt am Main, Germany., Drewry DH; Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, United States., Edwards AM; Structural Genomics Consortium, University of Toronto, Toronto, Canada., Edwards J; Janssen Pharmaceutical Research and Development LLC, Spring House, United States., Elkins JM; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom., Fischer C; Merck & Co., Inc., Boston, United States., Frye SV; Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, United States., Gollner A; Discovery Research, Boehringer Ingelheim, Biberach an der Riss, Germany., Grimshaw CE; Ched Grimshaw Consulting, LLC, Poway, United States., IJzerman A; Division of Medicinal Chemistry, Leiden University, Leiden, Netherlands., Hanke T; Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt, Frankfurt am Main, Germany., Hartung IV; Drug Discovery Pharmaceuticals, Bayer AG, Berlin, Germany., Hitchcock S; Takeda California Inc., San Diego, United States., Howe T; J&J Innovation Centre, London, United Kingdom., Hughes TV; J&J Innovation Centre, London, United Kingdom., Laufer S; Department of Pharmaceutical Chemistry, Eberhard Karls Universität Tübingen, Tübingen, Germany., Li VM; Drug Discovery Pharmaceuticals, Bayer AG, Wuppertal, Germany., Liras S; Worldwide Medicinal Chemistry, Pfizer, Cambridge, United States., Marsden BD; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.; Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom., Matsui H; Takeda Pharmaceutical Company Ltd, Fujisawa, Japan., Mathias J; Worldwide Medicinal Chemistry, Pfizer, Cambridge, United States., O'Hagan RC; Merck & Co., Inc., Boston, United States., Owen DR; Worldwide Medicinal Chemistry, Pfizer, Cambridge, United States., Pande V; Discovery Sciences, Janssen-Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium., Rauh D; Fakultät für Chemie und Chemische Biologie, Technische Universität Dortmund, Dortmund, Germany., Rosenberg SH; AbbVie, North Chicago, United States., Roth BL; The National Institute of Mental Health Psychoactive Active Drug Screening Program, University of North Carolina Chapel Hill School of Medicine, Chapel Hill, United States., Schneider NS; Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt, Frankfurt am Main, Germany., Scholten C; Drug Discovery Pharmaceuticals, Bayer AG, Berlin, Germany., Singh Saikatendu K; Takeda California Inc., San Diego, United States., Simeonov A; National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, United States., Takizawa M; Takeda Pharmaceutical Company Ltd., Fujisawa, Japan., Tse C; AbbVie, North Chicago, United States., Thompson PR; Department of Biochemistry and Pharmacology, University of Massachusetts Medical School, Worcester, United States., Treiber DK; Eurofins DiscoverX, Sane Diego, United States., Viana AY; Discovery Research, Boehringer Ingelheim, Ingelheim am Rhein, Germany., Wells CI; Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, United States., Willson TM; Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, United States., Zuercher WJ; Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, United States., Knapp S; Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt, Frankfurt am Main, Germany., Mueller-Fahrnow A; Drug Discovery Pharmaceuticals, Bayer AG, Berlin, Germany.
Publikováno v: ELife [Elife] 2018 Apr 20; Vol. 7. Date of Electronic Publication: 2018 Apr 20.
Zobrazit plný text záznamu
6
Akademický článek
Construction of an Integrated Teaching Case Library for Pharmaceutical Education: A Case Study on the Development of Anti- SARS-Cov-2 Drugs.
Autor: Peng Zhan1 zhanpeng1982@sdu.edu.cn, Xinyong Liu1
Publikováno v: University Chemistry. 2023, Vol. 38 Issue 12, p10-17. 8p.
Zobrazit plný text záznamu
7
Akademický článek
A fragment-based approach to identifying S-adenosyl-l-methionine -competitive inhibitors of catechol O-methyl transferase (COMT).
Autor: Lanier M; Medicinal Chemistry, ‡Structural Biology, §Discovery Biology, ∥Analytical Chemistry, Takeda California Inc. , 10410 Science Center Drive San Diego California 92121, United States., Ambrus G, Cole DC, Davenport R, Ellery J, Fosbeary R, Jennings AJ, Kadotani A, Kamada Y, Kamran R, Matsumoto S, Mizukami A, Okubo S, Okada K, Saikatendu K, Walsh L, Wu H, Hixon MS
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2014 Jun 26; Vol. 57 (12), pp. 5459-63. Date of Electronic Publication: 2014 Jun 04.
Zobrazit plný text záznamu
10
Akademický článek
Nuclear magnetic resonance structure shows that the severe acute respiratory syndrome coronavirus-unique domain contains a macrodomain fold.
Autor: Chatterjee A; Department of Molecular Biology, Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California 92037, USA., Johnson MA, Serrano P, Pedrini B, Joseph JS, Neuman BW, Saikatendu K, Buchmeier MJ, Kuhn P, Wüthrich K
Publikováno v: Journal of virology [J Virol] 2009 Feb; Vol. 83 (4), pp. 1823-36. Date of Electronic Publication: 2008 Dec 03.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje